Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 17:10.1007/s40615-024-02248-x.
doi: 10.1007/s40615-024-02248-x. Online ahead of print.

Exploring Racial and Ethnic Differences in Utilization of Medications for Obesity Management in a Nationally Representative Survey

Kimberly Narain  1   2   3 , Christopher Scannell  4   5
Affiliations

Exploring Racial and Ethnic Differences in Utilization of Medications for Obesity Management in a Nationally Representative Survey

Kimberly Narain et al. J Racial Ethn Health Disparities. .

Abstract

Background: The burden of obesity falls disproportionately on some racial and ethnic minority groups.

Objective: To assess for racial and ethnic differences in the utilization of obesity-management medications among clinically eligible individuals.

Design: Medical Expenditure Panel Survey (2011-2016, 2018 and 2020) data and a cross-sectional study design was used to assess for racial and ethnic differences in obesity-management medication utilization. Descriptive statistics and multivariable logistic regression models were used to identify the association of race and ethnicity with obesity-management medication utilization. Adjusted models controlled for demographics, socioeconomic status, obesity class, diabetes status, number of chronic conditions, insurance status, and geographic region.

Participants: Adults with a BMI ≥ 30 kg/m2 and individuals with a BMI ≥ 27 kg/m2 with ≥ 1 weight-related condition.

Main measures: The primary outcome measure was utilization of an FDA-approved medication for obesity-management during the study period. The primary independent predictor was race and ethnicity. Separate indicator variables were created for each racial and ethnic group (Non-Hispanic Asian, Non-Hispanic Black, Hispanic, and Non-Hispanic White (reference group)).

Key results: In adjusted analyses, Asian (aOR, 0.36; 95% CI, 0.16 to 0.77; P < 0.01), Black (aOR, 0.51; 95% CI, 0.39 to 0.68; P < 0.001) and Hispanic individuals (aOR, 0.70; 95% CI, 0.49 to 0.98; P = 0.04) had significantly lower odds of utilizing obesity-management medications compared to White individuals.

Conclusions: The results of this study suggest that there are racial and ethnic disparities in the use of obesity-management medications.

Keywords: Disparities; Ethnicity; Medications; Obesity; Race.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics Approval: The study protocol was exempted from review by the University of California Los Angeles Institutional Review Board. MEPS has been reviewed and approved by the Westat IRB, established under a multi-project assurance (MPA M-1531) granted by the Office for Protection from Research Risks, (OPRR). The project is reviewed and the approval renewed annually. Consent to Publish: Not applicable. Personal identifying information are removed before information from the survey is made available to researchers. Competing Interests: The authors have no relevant financial or non-financial interests to disclose.

Similar articles

See all similar articles

References

    1. Kabiri M, Sexton Ward A, Ramasamy A, et al. Simulating the fiscal impact of anti-obesity medications as an obesity reduction strategy. Inquiry. 2021;58:46958021990516. 10.1177/0046958021990516. - DOI - PMC - PubMed
    1. Ward ZJ, Willett WC, Hu FB, Pacheco LS, Long MW, Gortmaker SL. Excess mortality associated with elevated body weight in the USA by state and demographic subgroup: A modelling study. EClinicalMedicine. 2022;48:101429. Published 2022 Apr 28. 10.1016/j.eclinm.2022.101429 - DOI - PMC - PubMed
    1. CDC. Obesity is a Common, Serious, and Costly Disease. Centers for Disease Control and Prevention. 2022. https://www.cdc.gov/obesity/data/adult.html. Accessed February 1, 2024.
    1. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203. 10.4158/EP161365.GL. - DOI - PubMed
    1. Bersoux S, Byun TH, Chaliki SS, Poole KG. Pharmacotherapy for obesity: What you need to know. Cleve Clin J Med. 2017;84(12):951–8. 10.3949/ccjm.84a.16094. - DOI - PubMed